Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of “Moderate Buy” from Brokerages

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has earned a consensus recommendation of “Moderate Buy” from the twenty-five analysts that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation and nineteen have given a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $299.48.

A number of brokerages have weighed in on ALNY. Chardan Capital reaffirmed a “buy” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 11th. Morgan Stanley boosted their target price on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a report on Friday, February 14th. Raymond James upped their price target on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Finally, William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 663 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the sale, the executive vice president now directly owns 14,321 shares of the company’s stock, valued at approximately $3,654,862.41. The trade was a 4.42 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Jeffrey V. Poulton sold 967 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $246,749.39. Following the transaction, the chief financial officer now directly owns 32,786 shares in the company, valued at approximately $8,366,003.62. This represents a 2.86 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 81,356 shares of company stock worth $22,498,551 over the last three months. 1.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ALNY. GF Fund Management CO. LTD. purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter worth approximately $637,000. Focus Partners Advisor Solutions LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $203,000. Worldquant Millennium Advisors LLC boosted its position in Alnylam Pharmaceuticals by 156.6% during the 4th quarter. Worldquant Millennium Advisors LLC now owns 150,191 shares of the biopharmaceutical company’s stock worth $35,341,000 after purchasing an additional 91,671 shares during the period. Zurich Insurance Group Ltd FI acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at $6,583,000. Finally, Vident Advisory LLC raised its position in Alnylam Pharmaceuticals by 21.2% in the fourth quarter. Vident Advisory LLC now owns 1,327 shares of the biopharmaceutical company’s stock valued at $312,000 after purchasing an additional 232 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Trading Down 0.2 %

Shares of NASDAQ:ALNY opened at $250.59 on Monday. The company has a market cap of $32.44 billion, a PE ratio of -115.48 and a beta of 0.35. The company’s 50 day moving average is $254.14 and its two-hundred day moving average is $263.05. Alnylam Pharmaceuticals has a 52 week low of $141.98 and a 52 week high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Equities analysts predict that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.